Close Menu

NEW YORK (GenomeWeb) – Goldman Sachs today upgraded shares of Alere to a Buy rating, but downgraded Quest Diagnostics' shares to Neutral. 

In a research note, analyst Isaac Ro upgraded Alere from a previous Neutral rating and said that he believes that Alere's new management has brought focus to the firm's new products, streamlined its cost structure, and reduced its debt. As a result, he anticipates revenues to grow about 6 percent between the firm's fiscal years 2015 and 2018, and EPS to grow 17 percent during the same period. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Associated Press reports that a state board in Texas has asked ANDE, a maker of rapid DNA machines, to halt its work there.

James Wyngaarden, the former director of the US National Institutes of Health, has died at 94, according to Duke University School of Medicine.

Researchers find that a 30-year-old skull comes from a narwhal-beluga hybrid, according to Science News.

In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.